Drug Formulation Development

SRI Biosciences has the experience and expertise to solve challenging formulation and drug delivery problems. We address the cost parameters and regulatory requirements for formulating new drugs, and we look for simple, economical solutions to dosage design challenges. Our staff has extensive industry experience relating to all types of dosage forms and has worked with new chemical entities, OTC products, generic products, and line extensions. Protection of proprietary information is routinely incorporated into our procedures.

We start with an understanding of the bulk drug’s physical and chemical properties then screen the compound to determine its permeability characteristics and susceptibility to metabolizing enzymes.

Once the pharmaceutical profile of the drug has been determined, the appropriate route of administration can be identified and designed. Excipients are selected to overcome potential problems in manufacturing and stability, and to address factors impacting delivery issues such as solubility and absorption.

Bench studies are then performed on pilot batches to establish excipient compatibility and dosage form specifications. The final formulation design is optimized to take into account the pharmacokinetic properties of absorption, distribution, metabolism, and excretion.

Dosage forms include solutions, capsules, tablets, emulsions, suspensions, and semisolids. We have developed spray-dried, microencapsulated, and microfluidized formulations. We have also developed specialized alternative drug delivery systems such as bioadhesive nasal gels, biodegradable implants, enteric-coated capsules and tablets, topical gels, and multiparticulate systems.

Projects

bioscience workers in a lab

SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.

scientist checking a batch of vaccines

SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.

scientist working with a chelating agent

A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.

hand holding a petri dish of bacterial culture up to the light

Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.

Press Releases

Mario Geysen

SRI International, an independent nonprofit research and development organization, announced today that H. Mario Geysen, Ph.D., has joined SRI International's Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.

Jia-Hwa Fang

Jia-Hwa Fang, Ph.D., has joined SRI Biosciences as Director of Clinical Manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical trial materials.

SRI International, an independent nonprofit research and development institute, today announced that Joseph Perrone, Sc.D., has joined SRI’s International's Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia.

Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.

SRI International has acquired Quality Clinical Labs (QCL), the only commercial laboratory of its type in California performing clinical pathology analyses in compliance with Good Laboratory Practice (GLP) regulations. QCL specializes in clinical hematology and chemistry evaluations.

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute (NHLBI), one of the National Institutes of Health.

A presentation on strategic collaboration opportunities with SRI's Biosciences Division. SRI's well-funded researchers operates a nonprofit pharmaceutical organization and have the resources to provide complete drug discovery and development capabilities — from "Idea to IND®.

SRI has regained from Sanofi-Aventis all rights to tirapazamine, a cancer drug that reached Phase III clinical trials. The drug is a bioreductively-activated, hypoxia-selective small molecule that acts primarily in hypoxic regions of tumors.

girl

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

SRI In the News

The Right Formulation - and How to Get There (PDF)

This article by Gita Shankar, Ph.D., director of formulations R&D in SRI Biosciences, reports on the objective of drug formulation.